Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

NCT05617755 is registered in ClinicalTrials.gov with Arsenal Biosciences, Inc. as lead sponsor.

NCT NCT05617755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05617755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
Lead sponsor
Arsenal Biosciences, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 29, 2022
Completion date
February 28, 2027
Enrollment
19 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal neoplasm, carcinoma, ovarian epithelial, fallopian tube neoplasms, genital neoplasm, female, neoplasms, glandular and epithelial, ovarian diseases, ovarian neoplasms, peritoneal neoplasms, recurrence